Standard treatment
Radiotherapy
Directed radiation used to kill or control cancer cells in a defined area.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
What is it?
Radiotherapy may be given as primary therapy, before or after surgery, or to control symptoms.
Planning uses imaging so that the dose is directed at the tumor and as minimal as possible to healthy tissue.
The radiation beam is directed at the target area in a scheduled number of sessions.
How it works
The radiation beam is directed at the target area in a scheduled number of sessions. Planning is carried out by the radiation oncology team together with medical physicists.
Position in the treatment pathway: Can be at almost any point on the treatment pathway, depending on the goals and location of the disease.
Which cancers is it usually discussed for?
Lung Cancer
Lung cancer is divided into non-small-cell and small-cell groups, and molecular markers strongly shape which treatment options are discussed.
Open cancer page
Stomach Cancer
Stomach cancer is most often adenocarcinoma, and HER2, PD-L1, MSI/MMR and CLDN18.2 status can change which treatment options are discussed.
Open cancer page
Lymphoma
Lymphoma is a malignancy of the lymphatic system with many subtypes, and accurate pathological classification determines the direction of treatment.
Open cancer page
Multiple Myeloma
Multiple myeloma is a malignancy of plasma cells in the bone marrow, with cytogenetic markers that matter when treatment strategy is considered.
Open cancer page
Usually considered
- Diseases are limited to certain areas that can be targeted.
- Need for control of symptoms such as pain or bleeding.
- General conditions that allow daily sessions.
Usually not a candidate
- The spread of the disease is very wide and cannot be safely targeted.
- History of radiation in the same area where the tolerance limit has been reached.
What is the process like?
Preparation 1
Planning imaging (simulation).
Preparation 2
Consistent body position marking.
Monitoring
Periodic evaluation during the session.
All preparation
- Planning imaging (simulation).
- Consistent body position marking.
All monitoring
- Periodic evaluation during the session.
- Repeat imaging to assess response.
Risks and points to watch
Side-effect notes, not a complete list
- Side effects are generally limited to the irradiated area.
- Fatigue and skin reactions may appear.
- Long-term effects depend on the area and dose.
What needs to be checked?
Cost and access
Cost figures depend heavily on location, facility and payer. We do not show estimated figures on this page; what can be prepared first are the questions.
Providers and clinical trials
Access status not yet verified
NCT05675410Phase 3Combination regimen
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lymphoma | Immunotherapy, Radiotherapy, Chemotherapy
United States, Canada, Puerto Rico417 registry sites
Why this appears: Appears because it is recorded for Lymphoma, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05675410Not verified
NCT06124157Phase 2Combination regimen
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Lymphoma | Targeted therapy, Radiotherapy, Chemotherapy
United States, Australia, Canada +1159 registry sites
Why this appears: Appears because it is recorded for Lymphoma, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06124157Not verified
NCT07007182Phase 2Combination regimen
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Stomach Cancer | Targeted therapy, Radiotherapy
China1 registry sites
Why this appears: Appears because it is recorded for Stomach Cancer, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07007182Not verified
NCT07135882Phase 3Radiotherapy
Primary Radiotherapy In MEtastatic Lung Cancer
Lung Cancer | Radiotherapy, Chemotherapy
Australia2 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, the treatment category is Radiotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07135882Not verified
NCT07770100Phase 2Combination regimen
Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)
Lung Cancer, Stomach Cancer | Immunotherapy, Stereotactic body radiotherapy (SBRT), Radiotherapy
United States1 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07770100Not verified
NCT07554339Phase 3Combination regimen
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Lung Cancer | biomarker: KRAS | Immunotherapy, Radiotherapy, Chemotherapy
United States, Argentina, Australia +1595 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07554339Not verified
Questions for the doctor
- Which areas will be illuminated and how many sessions?
- What side effects are most likely to occur in this area?
- Is this radiotherapy aimed at curing or controlling symptoms?
Sources
- NCI Dictionary of Cancer Terms(lembaga)
Is Radiotherapy relevant for my case?
Ask for an initial review. We will explain which documents and markers need to be completed before discussion with a doctor.
Upload reports
Photos or PDFs of pathology, biomarkers, imaging and treatment history.
Case structured
Documents are turned into a structured case summary.
Navigator review
A human navigator checks completeness before anything is shared.
Provider review
With your consent, the case is discussed with providers for assessment and a written quote.
Is Radiotherapy relevant for my case?
Ask for an initial review. We will explain which documents and markers need to be completed before discussion with a doctor.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- MGMT
Biomarker
Reason: Related through a biomarker
- radioterapi
Service
Reason: Related to this page
- MGMT methylated
Molecular alteration
Reason: Related to this page
To check
- CT scan
Diagnostic test
Reason: Memerlukan pemeriksaan
- MRI
Diagnostic test
Reason: Memerlukan pemeriksaan
- Newly diagnosed lung cancer
Decision situation
Reason: Mungkin memerlukan
- Lung cancer that is still operable
Decision situation
Reason: Mungkin memerlukan
- PET-CT
Diagnostic test
Reason: Memerlukan pemeriksaan
- Locally advanced lung cancer
Decision situation
Reason: Mungkin memerlukan
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.